Global Anticoagulant Reversal Drugs Market Report, 2017-2025 - Market Projected to Grow at a CAGR of 11.5% During 2019-2025 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Anticoagulant Reversal Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.

The report predicts the global anticoagulant reversal drugs market to grow with a CAGR of 11.5 % over the forecast period from 2019-2025.

The report on the global anticoagulant reversal drugs market provides qualitative and quantitative analysis for the period from 2017 to 2025. The study on anticoagulant reversal drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on anticoagulant reversal drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global anticoagulant reversal drugs market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global anticoagulant reversal drugs market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

• Rise in the prevalence of atrial fibrillation and cardiovascular disease
• Growing aging population

2) Restraints

• Availability of the high cost of the patent drugs

3) Opportunities

• Many companies are taking initiative to launch the drug, which is used for reversing the effect of factor Xa inhibitors

What does this report deliver?

1. Comprehensive analysis of the global as well as regional markets of the anticoagulant reversal drugs market.

2. Complete coverage of all the segments in the anticoagulant reversal drugs market to analyze the trends, developments in the global market and forecast of market size up to 2025.

3. Comprehensive analysis of the companies operating in the global anticoagulant reversal drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Key Topics Covered:

1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

2.1. Anticoagulant Reversal Drugs Market Highlights

2.2. Anticoagulant Reversal Drugs Market Projection

2.3. Anticoagulant Reversal Drugs Market Regional Highlights

3. Global Anticoagulant Reversal Drugs Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter's Five Forces Analysis

3.4. Growth Matrix Analysis

3.4.1. Growth Matrix Analysis by Product Type

3.4.2. Growth Matrix Analysis by Distribution Channel

3.4.3. Growth Matrix Analysis by Region

3.5. Value Chain Analysis of Anticoagulant Reversal Drugs Market

4. Anticoagulant Reversal Drugs Market Macro Indicator Analysis

5. Global Anticoagulant Reversal Drugs Market by Product Type

5.1. Prothrombin Complex Concentrates

5.2. Vitamin K

5.3. Protamine

5.4. Tranexamic Acid

5.5. Idarucizumab

5.6. Andexxa

5.7. Other Product Types

6. Global Anticoagulant Reversal Drugs Market by Distribution Channel

6.1. Hospital Pharmacies

6.2. Retail Pharmacies

6.3. Others Distribution Channels

7. Global Anticoagulant Reversal Drugs Market by Region 2019-2025

7.1. North America

7.2. Europe

7.3. Asia-Pacific

7.4. RoW

8. Company Profiles and Competitive Landscape

8.1. Competitive Landscape in the Global Anticoagulant Reversal Drugs Market

8.2. Companies Profiled

8.2.1. Bausch Health Companies, Inc.

8.2.2. Pfizer, Inc.

8.2.3. Fresenius Kabi AG

8.2.4. Amneal Pharmaceuticals, Inc.

8.2.5. Boehringer Ingelheim GmbH

8.2.6. CSL Limited

8.2.7. Octapharma AG

8.2.8. Portola Pharmaceuticals, Inc.

8.2.9. Perosphere Pharmaceuticals, Inc.

9. Appendix

9.1. Primary Research Findings and Questionnaire

For more information about this report visit https://www.researchandmarkets.com/r/snjr3c